Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Kleen Hy-Dro-Gen Inc. Is Pleased to Announce Dual ISO 9001:2015 and TSSA Certifications, Bolstering Operational Quality and Technical Safety Governance

    August 5, 2026

    Skye Africa Intelligence and ECSA-HC Sign Memorandum of Understanding to Scale AI-Enabled Health Solutions

    August 5, 2026

    New Ebola vaccine enters human trial as Congo cases rise

    August 5, 2026
    Cairo WeeklyCairo Weekly
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Cairo WeeklyCairo Weekly
    Home » OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position
    ACCESS Newswire

    OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position

    June 15, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    PHILADELPHIA, PA / ACCESSWIRE / June 15, 2023 / OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.

    Envision Pharma Group, Thursday, June 15, 2023, Press release picture

    “I am excited about continuing the innovative collaboration between Envision and OKRA.ai along with Yahya as a senior leader as it further solidifies our Envision commitment to the expansion of OKRA.ai and leadership in the AI and technical space,” shares Meg Heim, CEO of Envision Pharma Group. “His leadership is critical to our vision to accelerate the delivery of our compelling combination of technology-enabled capabilities and solutions to clients as we continue to strengthen our offerings across the product life cycle, but more importantly to support patients in their journey to health and wellness.”

    Anvar joined OKRA.ai in 2019, heading the Data Science team. During his tenure, he has led the development of AI solutions across OKRA.ai’s portfolio of products and services. Prior to joining the company, he served as the principal investigator of preclinical personalized medicine at Leiden University Medical Center. He has over 14 years of experience in the healthcare sector and is the author of over 30 peer-reviewed scientific articles. Anvar holds a PhD in Computational Biology from the faculty of Medicine at Leiden University, and an MSc in Bioinformatics and Artificial Intelligence from Brunel University.

    Anvar shares, “It is an absolute privilege to be leading the AI insights and science at Envision and pushing the boundaries of what AI has to offer to better patients’ outcomes. Making an impact through solutions that provide actionable, explainable insights is what we thrive for. There is no better time for new beginnings than today, and I’m so excited to be working with the Envision team to transform the industry as we know it.”

    Dr. Loubna Bouarfa, Head of AI & Innovative Platforms at Envision, shares, “It was a pleasure to work with Yahya; he has been an exceptional leader of the Data Science team at OKRA.ai. His role has now expanded to cover AI insights and scientific expertise across the entire Envision organization following our recent acquisition. I look forward to working with him in driving AI innovation and propelling Envision to new heights.”

    About Envision Pharma Group

    Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

    Contact Information:

    Colleen Carter
    Associate Director, Communications, Office of CEO
    colleen.carter@envisionpharma.com
    1 (508) 505 8856

    SOURCE: Envision Pharma Group

    .

    Related Posts

    Kleen Hy-Dro-Gen Inc. Is Pleased to Announce Dual ISO 9001:2015 and TSSA Certifications, Bolstering Operational Quality and Technical Safety Governance

    August 5, 2026

    Review of 31 Studies Finds Vegan Dog Food and Vegan Cat Food Are Well Digested

    July 31, 2026

    U.S. Polo Assn. Sponsors the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup as Official Apparel Partner

    July 22, 2026

    GA-ASI and KONGSBERG Advance JSM Integration for MQ-9B

    July 20, 2026

    U.S. Polo Assn. Returns to 2026 DMMI Royal Charity Polo Cup as Official Apparel and Team Sponsor

    July 14, 2026

    U.S. Polo Assn. Celebrates 250 Years of American Spirit and Collaborates with ESPN on ‘Polo in America’ Broadcast Special

    July 2, 2026
    Latest Headlines

    New Ebola vaccine enters human trial as Congo cases rise

    August 5, 2026

    NOVA SCOTIA, CANADA / RankWire.AI / – Moderna has launched an early-stage trial of a…

    Brent and WTI extend losses after sharp crude market selloff

    August 5, 2026

    SINGAPORE / RankWire.AI / – Oil prices fell further on Wednesday after a steep two-day…

    Fuego volcano eruption puts Guatemala regions on red alert

    August 5, 2026

    GUATEMALA / RankWire.AI / – Guatemala raised the alert to its highest level in three…

    OECD inflation falls to 4.2% and energy price pressures cool

    August 5, 2026

    PARIS / RankWire.AI / – Annual inflation across OECD economies slowed to 4.2% in June…

    © 2026 Cairo Weekly | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.